Sign in
Taking peopleNo phase

The Impact of Fast Antimicrobial Sensitivity Testing Tools on Stewardship Antibiotic and Clinical Outcome (ACT-FAST)

Key facts

Who runs it
Istituto Clinico Humanitas
Where
Italy1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
400 people, planned
Started
19 Mar 2026
Expected to end
19 Mar 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Diagnostic Test: Rapid Antimicrobial Susceptibility Testing (R-AST) guided Stewardship
  • Standard of Care (SOC)
Record updated
24 June 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Patients admitted to emergency department or hospitalized for any cause in participating hospitals with clinically suspected BSI and positive blood culture
  • At least 18 years of age

Who cannot take part

  • Have previously taken part in this trial
  • Patient with severe or terminal disease with life expectancy shorter than 48 h
  • Concurrently participating in the active phase of a study considered incompatible
  • Have an existing directive to withhold life-sustaining treatment, in relation to antibiotic use

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The ACT-FAST study aims to compare commercially available Rapid Antimicrobial Susceptibility Testing (R-AST) tools with the current standard of care for patients with Bloodstream Infections (BSI). The primary objective is to evaluate whether "early targeted" antibiotic prescriptions, guided by these rapid tests, can improve antimicrobial stewardship and patient clinical outcomes.

Read full original descriptionShow less

To facilitate the evaluation of various diagnostic tools-including those currently on the market and those emerging in the near future-this study utilizes an adaptive clinical trial platform. This flexible design allows for the continuous assessment of different R-AST technologies within a single master protocol, ensuring that the most effective diagnostic strategies are identified efficiently.

The 2 groups in the trial

  • Experimental armTreatment being tested

    Diagnostic approach to blood cultures using rapid microbiological diagnosis testing (R-AST)

    Treatment: Diagnostic Test: Rapid Antimicrobial Susceptibility Testing (R-AST) guided Stewardship

  • Standard of careExisting treatment, for comparison

    Diagnostic approach to blood cultures using the standard method

    Treatment: Standard of Care (SOC)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Impact of Fast Antimicrobial Sensitivity Testing Tools on Stewardship Antibiotic and Clinical Outcome: a Randomized Clinical Trial Within an Adaptive Platform Trial for Patients With Bloodstream Infections
Record updated
24 June 2026